Abstract: Benzoylamides of the general formula (I) are described as herbicides. In this formula (I), B, X1 and X2 represent N, O or S(O)n, R, Ra, Rb, Rc, Rd and IV represent radicals such as hydrogen, halogen, (C1-C6)-alkyl, (C1-C6)-alkyloxy and cyano.

Abstract: A formulation for oral administration comprises an expectorant, an analgesic, and at least one additional active ingredient having a modified release providing a therapeutic effect for each of the active ingredients for up to 12 hours.

Abstract: Plant treatment products include a plant treatment component and, preferably mixed with, a microbial fermentation product. The microbial fermentation product includes cellular material of cultured microorganisms and one or more anaerobic metabolite products of the cultured microorganisms. Preferably, the microbial fermentation product comprises a whole culture lysate of a microbial fermentation suspension culture, including liquid fermentation culture medium components and lysed microorganisms. The plant treatment component of the product includes one or more pesticides or plant growth regulators. Plant treatment products can be applied to or around plants or seeds to enhance growth, health, or productivity of the plants.

Abstract: Method for colouring hair comprising pretreating the hair with at least one primer composition before treating the hair with a polymeric hair colouring system.

Abstract: A method of treating skin is disclosed. The method includes topically applying to the skin a composition comprising 0.0001 wt. % to 5 wt. % of a kakadu plum fruit extract, and 0.0001 wt. % to 5 wt. % of an acai berry fruit extract.

Abstract: A compound 2,4-dichloro-N-[(3-chlorophenyl)carbamothioyl]benzamide, its synthesis, and its use as an insecticidal agent.

Abstract: A compound 2,4-dichloro-N-[(3-chlorophenyl)carbamothioyl]benzamide, its synthesis, and its use as an insecticidal agent.

Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

Abstract: An injectable, flowable composition, kits that include the same, and methods of medical treatment of a mammal (e.g., human) that include the administration of the same are provided.

Abstract: The present invention relates to a composition of a multivitamin, vitamins B and C, and a preparation method therefor, and in particular, to a composition of a multivitamin, vitamins B and C for stimulating gastrointestinal system motility and a preparation method therefor. The composition is suitable for preventing and/or treating the statuses or diseases related to a lack of gastrointestinal motility.

Abstract: The present disclosure concerns a method for preparing florasulam which involves treating a solution of 2,6-difluoroaniline in 1,2-propylene glycol with: a) sulfonyl chloride III and then b) a base to provide, after workup and isolation, florasulam (I) in yields of about 65-85%. The treatment of 2,6-difluoroaniline with sulfonyl chloride III and the base are conducted by controlled additions.

Abstract: Therapeutically-active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation, and therapeutically-active compositions and formulations for wound management, including wounds that are at high risk for infection. Strontium and beta hydroxybutyrate based compositions and formulations which can be topically applied.

Abstract: A control agent comprising, as an active ingredient, a specific quinoline derivative compound such as 8-fluoro-2,3-dimethyl-6-(1,1-dimethylethyl)-4-(methylcarbonyl)oxyquinoline, azoxystrobin, picoxystrobin, pyraclostrobin, kresoxim-methyl, trifloxystrobin, metominostrobin, orysastrobin, famoxadone, fluoxastrobin, pyribencarb, cyazofamid, amisulbrom, flutolanil, mepronil, isofetamid, fluopyram, carboxin, thifluzamide, fluxapyroxad, furametpyr, penflufen, penthiopyrad, boscalid, diflumetorim, fluazinam, ferimzone, fenpyroximate, or an acid addition salt of any of these compounds shows an excellent controlling effect on Mesostigmata mites.

Abstract: Disclosed are methods of treating a patient having Major Depressive Disorder (MDD) or Treatment Resistant Depression (TRD). The methods include administering to the patient a therapeutically effective amount of bupropion hydrobromide in extended-release form. The methods are more therapeutically effective in treating MDD or TRD than administration of an equivalent plasma dose of bupropion hydrochloride in extended-release form. In addition or alternatively, the therapeutically effective amount of bupropion hydrobromide reduces the incidence of one or more adverse events (anxiety, agitation and/or insomnia), when compared to the administration of the equivalent plasma dose of bupropion hydrochloride in extended-release form.

Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

Abstract: The present invention disclosed herein relates to synergistic bioactive compositions for treating neurological disorders. Particularly, the invention relates to anti-ischemic nutritional compositions. More particular, the invention relates to synergistic, efficient, nutritional compositions for treating cerebral ischemia comprising therapeutically active exogenous combination of a decarboxylated L-arginine called agmatine (AGM) and a bio-optimized palmitoylethanolamide (Bio-PEA) and salts thereof, wherein the decarboxylated L-arginine salt i.e., agmatine sulfate and bio-optimized palmitoylethanolamide (PEA) are present in a weight ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable excipients.

Abstract: The present application relates to the treatment of nematode infections. For example, the application relates to the use of compounds of Formula (III) as defined herein for treatment of a nematode infection or a disease, disorder or condition arising from a nematode infection.

Abstract: Provided are preparation and use of novel compounds available as main ingredients of a composition for promoting hair growth, wherein the novel compounds are 9-deoxo-31-O-demethyl-prolyl-FK506, 9-deoxo-36,37-dihydro-FK506, 31-O-demethyl-36,37-dihydro-FK506, 9-deoxo-31-O-demethyl-36,37-dihydro-FK506, 9-deoxo-FK520, 31-O-demethyl-FK520, 9-deoxo-31-O-demethyl-FK520, 9-deoxo-FK523, and 9-deoxo-31-O-demethyl-FK523.

Abstract: A compound 2,4-dichloro-N-[(3-chlorophenyl)carbamothioyl]benzamide, its synthesis, and its use as an insecticidal agent.

Abstract: The invention relates to lyophilized products and reconstituted emulsions for parenteral application, which comprise all the 13 essential vitamins (A, D, E, K1, C, B1, B2, B3, B5, B6, B7, B9, and B12) in a single container, as well as to methods for preparing them.